“LONG-TERM” SURVIVAL IN LIGHT-CHAIN MYELOMA WITH DIALYSIS THERAPY ALONE
- 1 October 1984
- journal article
- case report
- Published by Wiley in Australian and New Zealand Journal of Medicine
- Vol. 14 (5) , 676-677
- https://doi.org/10.1111/j.1445-5994.1984.tb05027.x
Abstract
We report a case of a 59 year old woman who presented in end-stage renal failure with lambda (lambda) light-chain myeloma (LLCM). Despite a large tumour burden, and refusal to accept cytotoxic chemotherapy, she was commenced on continuous ambulatory peritoneal dialysis (CAPD). With dialysis therapy alone she has shown considerable hematological improvement and remains well 18 months after diagnosis. The extremely poor prognosis attributed to light-chain myeloma is largely due to death from uremia. As the natural history of this disease in patients offered dialysis therapy is unknown, dialysis should not automatically be withheld from patients with LLCM.Keywords
This publication has 6 references indexed in Scilit:
- Long-Term Survival in Multiple MyelomaNew England Journal of Medicine, 1983
- RENAL FUNCTION IN PATIENTS WITH MULTIPLE MYELOMAMedicine, 1978
- Combination therapy for multiple myelomaCancer, 1977
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- Hemodialysis in MyelomatosisAnnals of Internal Medicine, 1973
- Peritoneal Dialysis in the Treatment of Renal Failure in Multiple MyelomaSouthern Medical Journal, 1971